Margaret K. Callahan
Yale New Haven Hospital
3 papers in the Anchorcite directory, published between 2013 and 2017, cited 18,074 times in total.
ORCID profileResearch topics
- Cancer Immunotherapy and Biomarkers · 3 papers
- Cutaneous Melanoma Detection and Management · 3 papers
- Melanoma and MAPK Pathways · 2 papers
- Immunotherapy and Immune Responses · 1 paper
Frequent co-authors
- Michael Andrew Postow · 3 papers
- Jedd D. Wolchok · 3 papers
- James Larkin · 2 papers
- Vanna Chiarion‐Sileni · 2 papers
- Rene C. Gonzalez · 2 papers
- Jean‐Jacques Grob · 2 papers
- Charles Lance Cowey · 2 papers
- Christopher D. Lao · 2 papers
Papers
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine · 2015 · 8,341 citations
BACKGROUND: Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab…
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2017 · 5,446 citations
BACKGROUND: Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival outcomes in this trial. METHODS:…
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2013 · 4,287 citations
BACKGROUND: In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the programmed death 1 [PD-1] receptor) produced durable tumor regression in a phase 1 trial. On the basis…
Metadata from OpenAlex (CC0).